Forte Biosciences Inc
Research Forte Biosciences Inc (FBRX) on Bullrun: market cap USD 1.58B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFBRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.58B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 75.86M
- Free cash flow-USD 18.81M
Valuation Snapshot
latest market cap is USD 1.58B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 69.38M | -USD 51.00M | n/a | -4.71 | USD 76.96M | n/a | USD 60.99M |
| FY2024 | USD 0 | -USD 35.48M | -USD 30.78M | n/a | -12.17 | USD 22.24M | n/a | USD 52.48M |
| FY2023 | n/a | -USD 31.48M | -USD 28.79M | n/a | -24.92 | USD 37.13M | n/a | USD 35.31M |
| FY2022 | n/a | -USD 13.88M | n/a | n/a | -0.8 | USD 41.10M | n/a | USD 38.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.58B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 353.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 145.19M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 29.87M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 21.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 31.58M | n/a | n/a | n/a |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Forte Biosciences Inc's market cap?
Forte Biosciences Inc's market capitalization is USD 1.58B.
What does Forte Biosciences Inc do?
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.